---
title: "Clinical data of COVID-19 infected patients"
author: "Group 05 - Daniel Gil, Luis Mart√≠n, Miguel Blanco, Natalia Feced, Xavi Chapatte"
format: 
  revealjs:
    height: 900
    width: 1600
    theme: simple
    transition: none
editor: visual
subtite: "A case of study for critically ill patients"
css: styles.css
---

## Introduction

**Covid-19**\

::: {style="font-size: 40px;"}
-   Caused by the [**SARS-CoV-2 virus**]{.fragment .highlight-red}, with varying severity globally.
- [**Symptoms**]{.fragment .highlight-red} include fever, cough, myalgia, fatigue, and severe respiratory failure in     critical cases.
:::


::: nonincremental

**Vaccines and Antiviral drugs**\

-   [**Vaccines**]{.fragment .highlight-red} have reduced the global burden of COVID-19 significantly.
-   Before widespread vaccination, [**antivirals**]{.fragment .highlight-red} played a key role in severe cases.
-   [**Paxlovid**]{.fragment .highlight-red} (SARS-CoV-2 main protease inhibitor) and [**Azduvine**]{.fragment .highlight-red}  emerged as a promising treatment, reducing severe outcomes and mortality.


:::


::: footer
Article 1 - ScienceDirect\
Article 2 - PMC]
:::

## Dataset

::: {.column width="40%"}

::: {style="font-size: 39px; text-align: justify;"}

\

- [**Clinical data**]{.fragment .highlight-red} from a medical center in China between December 2022 - January 2023.
- Dataset with a final number of 123 [**variables**]{.fragment .highlight-red} and 150 [**observations**]{.fragment .highlight-red}.
- Researchers concluded [**Paxlovid**]{.fragment .highlight-red} significantly improved patient outcomes.
- [**Our aim**]{.fragment .highlight-red}: Test the conclusion on publicly available data
- Explore parameters contributing to [**survival**]{.fragment .highlight-red} or [**death**]{.fragment .highlight-red}.
:::
:::

::: {.column width="27%"}
**Table 1**\
<iframe src="../results/table1_describe_01.html" width="100%" height="300"></iframe>
\
**Diseases**\
<iframe src="../results/table1_describe_02.html" width="100%" height="300"></iframe>
:::

::: {.column width="28%"}
**Table 2**\
<iframe src="../results/table1_describe_04.html" width="100%" height="300"></iframe>
\
**Symptoms**\
<iframe src="../results/table1_describe_03.html" width="100%" height="300"></iframe>
:::

------------------------------------------------------------------------

## Methodology

### Data Cleaning and Augmenting

-   Clean
-   Augment

------------------------------------------------------------------------

## Methodology

### Analysis

-   Data Description
-   Statistical Exploration
-   Most Significant against Paxlovid

------------------------------------------------------------------------

## Data Description

### Factors Influencing Mortality: Overview

\

::: rows
::: columns
::: {.column width="33%"}
<figure>![](images/05_key_plot_1-02.png){width="800"}</figure>
:::

::: {.column width="33%"}
<figure>![](images/05_key_plot_3-02.png){width="800"}</figure>
:::

::: {.column width="33%"}
<figure>![](images/05_key_plot_7-02.png){width="800"}</figure>
:::
:::
:::

------------------------------------------------------------------------

## Data Description

### Factors Influencing Mortality: Overview

\

::: rows
::: columns
::: {.column width="33%"}
<figure>![](images/05_key_plot_4-02.png){width="800"}</figure>
:::

::: {.column width="33%"}
<figure>![](images/05_key_plot_5-02.png){width="800"}</figure>
:::

::: {.column width="33%"}
<figure>![](images/05_key_plot_6-02.png){width="800"}</figure>
:::
:::
:::

------------------------------------------------------------------------

## Data Description

::: columns
::: {.column width="50%"}
### CT Severity Scores

<figure>![](images/05_key_plot_6-02.png){width="400"}</figure>
:::

::: {.column width="50%"}
### Early Onset Temperature

<figure>![](images/05_key_plot_7-02.png){width="350"}</figure>
:::
:::

------------------------------------------------------------------------

## Analysis

------------------------------------------------------------------------

## Analysis

### Paxlovid Exploration

::: columns
::: {.column width="50%"}
<figure>![](images/05_key_plot_6-02.png)</figure>
:::

::: {.column width="50%"}
<figure>![](images/05_key_plot_6-02.png)</figure>
:::
:::

------------------------------------------------------------------------

### Discussion and Conclusion

::: {style="margin-top: 100px;"}
:::

::: nonincremental
-   In the dataset no difference can be seen in the outcome regarding the antiviral treatment.

\

-   The lymphocyte count in day 7 is the factor that mostly improves survival in the dataset.

\

-   The biological problem has to be thought as complex and interconnected, so no easy conclusion can be obtained and more studies may be needed.
:::
